The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
(1976) · Medical Entomology and Zoology · Cited by 8,899
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,701
Lingjærde, O., Ahlfors, U. G., Bech, P., Dencker, S. J., & Elgen, K. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb10566.x · Cited by 1,705
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection
Oldendorf, W. (1971) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1971.221.6.1629 · Cited by 1,683
d -Serine is an endogenous ligand for the glycine site of the N -methyl- d -aspartate receptor
Mothet, J.-P., Parent, A. T., Wolosker, H., Brady, R. O., Linden, D. J., Ferris, C. D., Rogawski, M. A., & Snyder, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4926 · Cited by 1,137
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Malhotra, M. D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 680
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.572 · Cited by 490
Excitatory Amino Acid Neurotransmission: NMDA Receptors and Hebb-Type Synaptic Plasticity
Cotman, C. W., & Monaghan, D. T. (1988) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.11.030188.000425 · Cited by 488
Efficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
Self-citationGoff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Ketamine activates psychosis and alters limbic blood flow in schizophrenia
Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · NeuroReport · doi:10.1097/00001756-199504190-00011 · Cited by 434
Tsai, G., Lane, H.-Y., Yang, P., Chong, M.-Y., & Lange, N. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.012 · Cited by 342
Free d-aspartate and d-serine in the mammalian brain and periphery
Hashimoto, A., & Oka, T. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00019-1 · Cited by 330
Five-Factor Model of Schizophrenia Initial Validation
LINDENMAYER, J.-P., BERNSTEIN-HYMAN, R., & GROCHOWSKI, S. (1994) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199411000-00006 · Cited by 258
G. Moloney, M. (1998) · Natural Product Reports · doi:10.1039/a815205y · Cited by 255
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222
Self-citationHashimoto, A., Nishikawa, T., Konno, R., Niwa, A., Yasumura, Y., Oka, T., & Takahashi, K. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90476-2 · Cited by 211
(2002) · Wiley eBooks · doi:10.1002/0470854871 · Cited by 199
Meldrum, B. S. (1991) · Raven Press eBooks · Cited by 196
Goff, D. C., Henderson, D. C., Evins, A. E., & Amico, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Heresco-Levy, U., Ermilov, M., Shimoni, J., Shapira, B., Silipo, G., & Javitt, D. C. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.480 · Cited by 167
Self-citationThe Mount Sinai Conference on the Pharmacotherapy of Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., Lieberman, J. A., & Schooler, N. R. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006926 · Cited by 127
D-serine antagonized phencyclidine- and MK-801-induced stereotyped behavior and ataxia
Contreras, P. C. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90015-j · Cited by 124
Heresco‐Levy, U., & Javitt, D. C. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00129-4 · Cited by 121
Self-citationd-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia
Evins, A. E., Amico, E. T., Posever, T. A., Toker, R., & GOFF, D. C. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00220-1 · Cited by 120
Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia
Rosse, R. B., Theut, S. K., Banay‐Schwartz, M., Leighton, M. P., Scarcella, E., Cohen, C. G., & Deutsch, S. I. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198910000-00006 · Cited by 101
Tanii, Y., Nishikawa, T., Hashimoto, A. S., & Takahashi, K. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38840-3 · Cited by 101
Cascella, N. G., Macciardi, F. M., Cavallini, M. C., & Smeraldi, E. (1994) · Journal of Neural Transmission · doi:10.1007/bf01276429 · Cited by 91
In Vivo Evidence for the Link Between l ‐ and d ‐Serine Metabolism in Rat Cerebral Cortex
Takahashi, K., Hayashi, F., & Nishikawa, T. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031286.x · Cited by 78
Dual effect of glycine on NMDA-induced neurotoxicity in rat cortical cultures
McNamara, D., & Dingledine, R. J. (1990) · Journal of Neuroscience · doi:10.1523/jneurosci.10-12-03970.1990 · Cited by 66
Iwama, H., Takahashi, K., Kure, S., Hayashi, F., Narisawa, K., Tada, K., Mizoguchi, M., Takashima, S., Tomita, U., & Nishikawa, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6184 · Cited by 57
Amino acid levels in d-alanine-administered mutant mice lacking d-amino acid oxidase
Nagata, Y., Konno, R., & Niwa, A. (1994) · Metabolism · doi:10.1016/0026-0495(94)90059-0 · Cited by 52
Chronic high-dose glycine nutrition: effects on rat brain cell morphology
Shoham, S., Javitt, D. C., & Heresco‐Levy, U. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01046-5 · Cited by 36
Self-citationForty Years of Neurotransmitters: A Personal Account
Snyder, S. H. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.11.983 · Cited by 18
Glycine and d-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia
Shoham, S., Mazeh, H., Javitt, D. C., & Heresco‐Levy, U. (2004) · Brain Research · doi:10.1016/j.brainres.2004.01.022 · Cited by 13
Self-citation
Cited by
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Self-citationBuchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419
Self-citationGlutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
Olanzapine versus other atypical antipsychotics for schizophrenia
Komossa, K., Rummel-Kluge, C., Hunger, H., Schmid, F., Schwarz, S., Duggan, L., Kissling, W., & Leucht, S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006654.pub2 · Cited by 365
Metadata
- Authors
- Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2005-03
- Volume
- 57
- Issue
- 6
- Pages
- 577-585
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W2085223461
- Cited by
- 386
- References
- 48
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.